Table S1: List of Study Names and Study Numbers, Collaborators and References

Study	Study No.	Study Name (if applicable), Name and Institution of Collaborators, Reference
1	**A1, B1, C1**	African American Study of Kidney Disease and Hypertension (AASK) Tom Greene, PhD, Utah University, Salt Lake City, Utah, USA ***Reference***: Wright JT, Jr., Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288(19):2421-2431.
2	**A2**	Robert Toto, MD, University of Texas Southwestern Medical Center, Texas, USA ***Reference***: Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med. 2003;139(4):244-252.
3	**A3**	GG van Essen MD, University Hospital Groningen, Groningen, Netherlands ***Reference***: van Essen GG, Apperloo AJ, Rensma PL, et al. Are angiotensin converting enzyme inhibitors superior to beta blockers in retarding progressive renal function decline? Kidney Int Suppl. 1997;63:S58-62.
4	**A4**	The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group Guiseppe Maschio, MD, University Hospital, Verona, Italy ***Reference***: Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996;334(15):939-945.
5	**A5**	Anne Lise Kamper, Svend Strandgaard, University of Copenhagen, Copenhagen,Denmark ***Reference***: Kamper AL, Strandgaard S, Leyssac PP. Effect of enalapril on the progression of chronic renal failure. A randomized controlled trial. Am J Hypertens. 1992;5(7):423-430.
6	**A6**	Barry M. Brenner, Brigham and Women's Hospital, Boston, Massachusetts, USA ***Reference:*** Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med. 2003;139(4):244-252.
7	**A7**	Benno U. Ihle MBBS, FRACP, FJFICM; Priscilla S. Kincaid-Smith MD, DSc, The Royal Melbourne Hospital, Victoria, Australia ***Reference***: Ihle BU, Whitworth JA, Shahinfar S, Cnaan A, Kincaid-Smith PS, Becker GJ. Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial. Am J Kidney Dis. 1996;27(4):489-495.
8	**A8**	Thierry P. Hannedouche, MD, University Hospital, Strasbourg, France ***Reference***: Hannedouche T, Landais P, Goldfarb B, et al. Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. BMJ. 1994;309(6958):833-837.
9	**A9**	Hong Kong Study Using Valsartan in IgA Nephropathy (HKVIN) Philip Kam-Tao Li, MD, FRCP, FACP, Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, Hong Kong ***Reference***: Li PK, Leung CB, Chow KM, et al. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. Am J Kidney Dis. 2006;47(5):751-760.
10	**A10**	Fan Fan Hou, MD, PhD, Nanfang Hospital, Southern Medical University, Guangzhou, China ***Reference***: Hou FF, Zhang X, Zhang GH, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med. 2006;354(2):131-140.
11	**A11**	Manuel Praga, MD, Hospital 12 de Octubre, Madrid, Spain ***Reference***: Praga M, Gutierrez E, Gonzalez E, Morales E, Hernandez E. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol. 2003;14(6):1578-1583.
12	**A12**	Captopril in Diabetic Nephropathy Study (CSG) Roger A. Rodby, MD; Richard D. Rohde, BS, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, USA ***Reference***: Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329(20):1456-1462.
13	**A13**	Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Dick De Zeeuw, MD, PhD; Barry M. Brenner, MD; William Keane, MD, Brigham and Women's Hospital, Boston, Massachusetts, USA ***Reference***: Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861-869.

14	**A14**	Ramipril Efficacy In Nephropathy (REIN) Giuseppe Remuzzi, MD, FRCP; Piero Ruggenenti MD, Mario Negri Institute for Pharmacological Research, Clinical Research Centre for Rare Diseases, Ranica, Italy ***Reference***: Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet. 1999;354(9176):359-364.
15	**A15, B15**	Irbesartan in Diabetic Nephropathy Trial (IDNT) Ed Lewis, MD; Lawrence G. Hunsicker, MD, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, USA ***Reference***: Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New England Journal Medicine. 2001;345(12):851-860.
16	**B16, C16**	Appropriate Blood Pressure Control in Diabetes (ABCD) Robert W. Schrier, MD, Raymond O. Estacio, MD, University of Colorado, Denver, USA ***Reference***: Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 2000;23 Suppl 2:B54-64.
17	**B17**	Pietro Zucchelli, MD, Ospedale M. Malpighi, Bologna, Italy ***Reference***: Zucchelli P, Zuccala A, Borghi M, et al. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int. 1992;42(2):452-458.
18	**C18, D18**	Modification of Diet in Renal Disease (MDRD) Study A Gerald Beck, PhD, Cleveland Clinic Foundation, Cleveland, Ohio, USA ***Reference***: Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med. 1994;330(13):877-884.
19	**C19, D19**	Modification of Diet in Renal Disease (MDRD) Study B Gerald Beck, PhD, Cleveland Clinic Foundation, Cleveland, Ohio, USA ***Reference***: Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med. 1994;330(13):877-884.
20	**C20**	Ramipril Efficacy In Nephropathy (REIN-2) Giuseppe Remuzzi, MD, FRCP; Piero Ruggenenti, MD, Mario Negri Institute for Pharmacological Research, Clinical Research Centre for Rare Diseases, Ranica, Italy ***Reference***: Ruggenenti P, Perna A, Loriga G, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet. 2005;365(9463):939-946.
21-1	**E21-1**	Bart Maes, MD, PhD, University Hospital Gasthuisberg, Leuven, Belgium ***Reference***: Maes BD, Oyen R, Claes K, et al. Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. Kidney Int. 2004;65(5):1842-1849.
21-2	**E21-2**	James Donadio, MD; Fernando Fervenza, MD, Mayo Clinic, Rochester, Minnesota, USA ***Reference***: Donadio JV, Jr., Larson TS, Bergstralh EJ, Grande JP. A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy. J Am Soc Nephrol. 2001;12(4):791-799.
21-3	**E21-3**	James Donadio, MD; Fernando Fervenza, MD, Mayo Clinic, Rochester, Minnesota, USA ***Reference***: Donadio JV, Jr., Grande JP, Bergstralh EJ, Dart RA, Larson TS, Spencer DC. The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group. J Am Soc Nephrol. 1999;10(8):1772-1777.
21-4	**E21-4**	Gerald B. Appel, MD; Gershon Frisch, MD, New York Presbyterian Hospital, Columbia University, New York, USA ***Reference***: Frisch G, Lin J, Rosenstock J, et al. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrol Dial Transplant. 2005;20(10):2139-2145.
22-1	**E22-1**	Euro Lupus Nephritis Trial (ELNT) Frédéric A. Houssiau, MD, PhD, Cliniques Universitaires St-Luc and Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Belgium ***Reference*** : Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis and rheumatism. 2002;46(8):2121-2131.

22-2	**E22-2**	Tak-Mao Chan MD, University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong ***Reference***: Chan TM, Tse KC, Tang CS, Mok MY, Li FK. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol. 2005;16(4):1076-1084.
22-3	**E22-3**	Lupus Nephritis Collaborative Study (LNCS) Edmund Lewis, MD; John M. Lachin, ScD, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, USA ***Reference***: Lewis EJ, Hunsicker LG, Lan SP, Rohde RD, Lachin JM. A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N Engl J Med. 1992;326(21):1373-1379.
23-1	**E23-1**	Daniel C. Cattran, MD, FRCPC, University of Toronto, Canada ***Reference***: Cattran DC, Appel GB, Hebert LA, et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int. 1999;56(6):2220-2226.
23-3	**E23-3**	Daniel C. Cattran, MD, FRCPC, University of Toronto, Canada ***Reference***: Cattran DC, Appel GB, Hebert LA, et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int. 2001;59(4):1484-1490.
23-2	**E23-2**	Claudio Ponticelli, MD; Patrizia Passerini, MD; Gabriella Moroni, MD; Giuseppe Montogrino, MD, IRCCS Istituto Humanitas, Milan, Italy ***Reference***: Ponticelli C, Zucchelli P, Passerini P, et al. A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med. 1989;320(1):8-13.
23-4	**E23-4**	Claudio Ponticelli, MD; Patrizia Passerini, MD; Gabriella Moroni, MD; Giuseppe Montogrino, MD, IRCCS Istituto Humanitas, Milan, Italy ***Reference***: Ponticelli C, Zucchelli P, Passerini P, Cesana B. Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. The Italian Idiopathic Membranous Nephropathy Treatment Study Group. N Engl J Med. 1992;327(9):599-603.
23-5	**E23-5**	Claudio Ponticelli, MD; Patrizia Passerini, MD; Gabriella Moroni, MD; Giuseppe Montogrino, MD, IRCCS Istituto Humanitas, Milan, Italy ***Reference***: Ponticelli C, Altieri P, Scolari F, et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol. 1998;9(3):444-450.
23-6	**E23-6**	Claudio Ponticelli, MD; Patrizia Passerini, MD; Gabriella Moroni, MD; Giuseppe Montogrino, MD, IRCCS Istituto Humanitas, Milan, Italy ***Reference***: Ponticelli C, Passerini P, Salvadori M, et al. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. Am J Kidney Dis. 2006;47(2):233-240.
23-7	**E23-7**	Manuel Praga, MD, Grupo Español de estudio de la Nefropatía Membranosa ***Reference***: Praga M, Barrio V, Juarez GF, Luno J. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int. 2007;71(9):924-930.